Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate ...

Key Takeaways Shares of Edgewise Therapeutics fell sharply Wednesday after the company released data for its latest clinical ...

Analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for Edgewise Therapeutics in a research note issued on Wednesday, April 2nd. Leerink Partnrs analyst J. Schwartz now anticipates that the ...

Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 28.51%, which has investors questioning if this is right time to ...

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX ...

Shares of NASDAQ EWTX opened at $11.51 on Wednesday. Edgewise Therapeutics has a 1-year low of $11.50 and a 1-year high of $38.12. The stock’s 50-day moving average is $25.20 and its two-hundred ...

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Piper Sandler analyst Yasmeen Rahimi remains bullish on Edgewise Therapeutics (EWTX) and maintains an Overweight rating and $51 price target on ...

Edgewise Therapeutics is working on EDG-7500 as a possible new treatment that might work like current heart myosin inhibitors but have fewer side effects. But based on what we know so far about ...

Edgewise Therapeutics (EWTX) stock drops 17% after Scotiabank downgrades rating and cuts price target to $14. Read more here.

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive ...